Purpose of review: Sinonasal tumors are rare and heterogeneous diseases which pose challenges in diagnosis and treatment. Despite significant progress made in surgical, oncological, and radiotherapy fields, their prognosis still remains poor. Therefore, alternative strategies should be studied in order to refine diagnosis and improve patient care.
Recent findings: In recent years, in-depth molecular studies have identified new biological markers, such as genetic abnormalities and epigenetic variations, which have allowed to refine diagnosis and predict prognosis. As a consequence, new histological entities have been described and specific subgroup stratifications within the well-known histotypes have been made possible. These discoveries have expanded indications for immunotherapy and targeted therapies in order to reduce tumor spread, thus representing a valuable implementation of standard treatments. Recent findings in molecular biology have paved the way for better understanding and managing such rare and aggressive tumors. Although further efforts need to be made in this direction, expectations are promising.
Keywords: Biomarkers; INI-1; Immunotherapy; Intestinal-type adenocarcinoma (ITAC); Mucosal melanoma; Neuroendocrine carcinoma (SNEC); Olfactory neuroblastoma; PD-L1; Paranasal sinus cancer; Sinonasal undifferentiated carcinoma (SNUC); Targeted therapies.
© 2022. The Author(s).